These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 31679519)

  • 21. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
    Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING.
    Rueckert C; Rand U; Roy U; Kasmapour B; Strowig T; Guzmán CA
    FASEB J; 2017 Jul; 31(7):3107-3115. PubMed ID: 28396343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy.
    Berger G; Marloye M; Lawler SE
    Trends Mol Med; 2019 May; 25(5):412-427. PubMed ID: 30885429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
    Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
    Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALG2 regulates type I interferon responses by inhibiting STING trafficking.
    Ji W; Zhang L; Xu X; Liu X
    J Cell Sci; 2021 Dec; 134(24):. PubMed ID: 34787301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCV2 infection activates the cGAS/STING signaling pathway to promote IFN-β production and viral replication in PK-15 cells.
    Huang B; Zhang L; Lu M; Li J; Lv Y
    Vet Microbiol; 2018 Dec; 227():34-40. PubMed ID: 30473349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer.
    Mohseni G; Li J; Ariston Gabriel AN; Du L; Wang YS; Wang C
    Front Immunol; 2021; 12():781032. PubMed ID: 34858438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity.
    Kim JC; Liu X; Fitzgerald K; Eng JS; Orf J; O'Brien SA; Belmontes B; Casbon AJ; Novitskiy SV; Tarbell KV; DeVoss J; Egen JG
    Cancer Immunol Immunother; 2023 May; 72(5):1327-1335. PubMed ID: 36394642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death.
    Larkin B; Ilyukha V; Sorokin M; Buzdin A; Vannier E; Poltorak A
    J Immunol; 2017 Jul; 199(2):397-402. PubMed ID: 28615418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of dsDNA-induced innate immune responses by membrane trafficking.
    Saitoh T; Fujita N; Yoshimori T; Akira S
    Autophagy; 2010 Apr; 6(3):430-2. PubMed ID: 20215874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
    Rivera Vargas T; Benoit-Lizon I; Apetoh L
    Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING-mediated DNA sensing in cancer immunotherapy.
    Zhou X; Jiang Z
    Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.
    Bose D
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.
    Khoo LT; Chen LY
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30446584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.
    Kimura Y; Negishi H; Matsuda A; Endo N; Hangai S; Inoue A; Nishio J; Taniguchi T; Yanai H
    Cancer Sci; 2018 Sep; 109(9):2687-2696. PubMed ID: 29981256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.